Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Galectin-9 as a regulator of immune interactions in the tumor microenvironment and novel therapeutic target in biliary tract cancer.
Authors
Emilie AK Warren
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA
Emilie AK Warren , Jacklyn Hammons , Jessica M. Keilson , Megan Wyatt , Caroline Medin , Curtis Henry , Sarah Kulkarni , Yuan Liu , Brian Robinson , Alyssa Krasinskas , Shishir K. Maithel , Chrystal M Paulos , Gregory B. Lesinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 555)
DOI
10.1200/JCO.2024.42.3_suppl.555
Abstract #
555
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.
First Author: Wen-Zhuo He
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of liver metastases, tumor microenvironment, and treatment outcomes in patients with urothelial bladder cancer treated with tislelizumab.
First Author: Linlin Xu
Poster
2019 ASCO Annual Meeting
A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.
First Author: Vaibhav Sahai
Poster
2016 ASCO Annual Meeting
Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: a TCGA pan-cancer analysis.
First Author: Elia Seguí